Last reviewed · How we verify
PT2385
At a glance
| Generic name | PT2385 |
|---|---|
| Sponsor | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- [18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma (PHASE1)
- MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003) (PHASE2)
- A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) (PHASE1)
- HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma (PHASE2)
- PT2385-102 Food Effect Study of PT2385 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PT2385 CI brief — competitive landscape report
- PT2385 updates RSS · CI watch RSS
- Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) portfolio CI